The Bradley Foster & Sargent Inc. CT Cuts Stake in Eli Lilly and Co. (LLY)

The Bradley Foster & Sargent Inc. CT Cuts Stake in Eli Lilly and Co. (LLY)

Bradley Foster & Sargent Inc. CT reduced its stake in shares of Eli Lilly and Co. (NYSE:LLY) by 0.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,993 shares of the company’s stock after selling 100 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in Eli Lilly and were worth $2,809,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of LLY. PineBridge Investments L.P. boosted its position in shares of Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock valued at $108,000 after buying an additional 920 shares during the period. Integrated Wealth Management boosted its position in Eli Lilly and by 3.7% in the third quarter. Integrated Wealth Management now owns 1,389 shares of the company’s stock valued at $112,000 after buying an additional 50 shares during the last quarter. Financial Architects Inc boosted its position in Eli Lilly and by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock valued at $114,000 after buying an additional 61 shares during the last quarter. Tarbox Group Inc. boosted its position in Eli Lilly and by 0.7% in the third quarter. Tarbox Group Inc. now owns 1,539 shares of the company’s stock valued at $124,000 after buying an additional 11 shares during the last quarter. Finally, Pinkerton Retirement Specialists LLC acquired a new position in Eli Lilly and during the second quarter valued at approximately $132,000. Hedge funds and other institutional investors own 73.90% of the company’s stock.

Eli Lilly and Co. (NYSE:LLY) traded down 0.884% on Thursday, hitting $76.845. The company’s stock had a trading volume of 2,608,017 shares. The firm has a market cap of $81.28 billion, a price-to-earnings ratio of 33.425 and a beta of 0.25. The firm has a 50 day moving average of $72.28 and a 200 day moving average of $77.17. Eli Lilly and Co. has a 12 month low of $64.18 and a 12 month high of $83.79.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 25th. The company reported $0.88 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.96 by $0.08. The firm had revenue of $5.19 billion for the quarter, compared to analysts’ expectations of $4.23 billion. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.89 EPS. Equities research analysts forecast that Eli Lilly and Co. will post $3.54 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 10th. Stockholders of record on Wednesday, February 15th will be given a dividend of $0.52 per share. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend is Monday, February 13th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.68%. Eli Lilly and’s dividend payout ratio (DPR) is presently 88.70%.

LLY has been the subject of several recent analyst reports. Goldman Sachs Group Inc. upgraded Eli Lilly and from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $89.00 to $95.00 in a research report on Tuesday, September 27th. BMO Capital Markets restated an “outperform” rating and set a $94.00 target price on shares of Eli Lilly and in a research report on Tuesday, September 27th. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $89.00 target price for the company in a research report on Tuesday, September 27th. Leerink Swann restated a “buy” rating and set a $103.00 target price on shares of Eli Lilly and in a research report on Sunday, October 9th. Finally, Societe Generale restated a “hold” rating and set a $78.00 target price on shares of Eli Lilly and in a research report on Thursday, October 27th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Eli Lilly and currently has an average rating of “Buy” and a consensus price target of $88.24.

In related news, Director R David Hoover purchased 500 shares of the company’s stock in a transaction that occurred on Friday, December 16th. The stock was bought at an average price of $71.85 per share, for a total transaction of $35,925.00. Following the completion of the transaction, the director now owns 33,504 shares in the company, valued at approximately $2,407,262.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock in a transaction dated Friday, December 16th. The stock was sold at an average price of $72.59, for a total value of $14,518,000.00. Following the completion of the transaction, the insider now owns 125,649,408 shares of the company’s stock, valued at approximately $9,120,890,526.72. The disclosure for this sale can be found here. Insiders have sold 222,335 shares valued at $16,160,688.69 In the last 90 days. Company insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co. (NYSE:LLY).

Related posts

Leave a Comment